Compare ALZN & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALZN | PPBT |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | Israel |
| Employees | 7 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.4M |
| IPO Year | 2021 | 2014 |
| Metric | ALZN | PPBT |
|---|---|---|
| Price | $1.03 | $4.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $28.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 54.4K | 9.1K |
| Earning Date | 03-11-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $0.41 |
| 52 Week High | $8.22 | $5.18 |
| Indicator | ALZN | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 46.68 |
| Support Level | $1.03 | $3.70 |
| Resistance Level | $1.21 | $4.39 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 35.00 | 11.93 |
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.